Victoria Casado Echarren

DIAGNOSTICO, ESTUDIO DE EXTENSION Y MANEJO MULTIDISCIPLINAR DEL PACIENTE ONCOLOGICO/MANEJO Y PRESCRIPCION DE ONCOFARM/QT INTRAPERITONEAL/ MANEJO DE CITOSTATICOS/MANEJO DE INMUNOTERAPIA/MANEJO DE TRATAMIENTOS DIRIGIDOS/MANEJO DE COMPLICACIONES DEL CANCER Y URGENCIAS ONCOLOGICAS/ MANEJO DE TOXICIDAD DE ANTINEOPLASICOS/ LIDERAZGO EN COMITES MULTIDISCIPLINARES/FORMACION Y EXPERIENCIA EN ENSAYOS CLINICOS Y NUEVAS MOLECULAS/ EXPERIENCIA EN HABLIDADES EMOCIONALES Y PSICOONCOLOGIA

ENSAYOS CLINICOS/TESIS DOCTORAL

COLABORADOR DOCENTE UNIVERSIDAD AUTONOMA DE MADRID/UNIVERSIDAD ALFONSO X EL SABIO

"High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma". J Immunother Cancer 2024;12:e008325. doi:10.1136/jitc-2023-008325 Danny Rischin , Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf , Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier ,Thomas K Eigentler , Victoria Casado Echarren et al.

"Clinical experience with rucaparib after prior PARPi treatment: A subanalysis from the rucaparib access program in Spain by GEICO".

2022 Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, PurificaciÓn EstÉvezGarcÍa, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, Maria Luisa Sanchez Lorenzo; by American Society of Clinical Oncology. Visit abstracts.asco.org

"Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study ". Alfonso Yubero1*, Aranzazu Barquín2 , Purificación Estévez3 , Bella Pajares4 , Luisa Sánchez5 , Piedad Reche6 , Jesús Alarcón7 , Julia Calzas8 , Lydia Gaba9 , José Fuentes10, Ana Santaballa11, Carmen Salvador12, Luis Manso13, Ana Herrero14, Álvaro Taus15, Raúl Márquez16, Julia Madani17, María Merino18, Gloria Marquina19, Victoria Casado20, Manuel Constenla21, María Gutiérrez22, Alba Dosil23 and Antonio González-Martín5,BMC Cancer (2022) 22:1150 https://doi.org/10.1186/s12885-022-10191-5

"Dostarlimab for the treatment of endometrium cancer and other solid tumors" J. Rubio-Pérez1 , R. Hernández1 , T. Hernández1,2, B. Doger1,2, V. Casado1 and V. Moreno1,2 1 Medical Oncology, Fundación Jiménez Díaz University Hospital, Madrid, Spain; 2 START Madrid-FJD, Early Phase Clinical Trials Unit, Fundación Jiménez Díaz University Hospital, Madrid, Spain

Drugs of Today 2021, 57(3): 187-197: 1699-3993/2021 DOI: 10.1358/dot.2021.57.3.3233363

"Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial". Journal of Clinical Oncology Volume 42, Number 36 https://doi.org/10.1200/JCO.24.00668Antonio Gonzalez-Martin, MD1,2 ; Maria Jesus Rubio, MD ´ 2,3 ; Florian Heitz, MD4,5,6 ; Rene Depont Christensen, PhD ´ 2 ; Nicoletta Colombo, MD7,8,9 ; Toon Van Gorp, MD10,11 ; Margarita Romeo, MD2,12 ; Isabelle Ray-Coquard, MD13,14 ; Lydia Gaba, MD2,15 ; Alexandra Leary, MD14,16 ; Luis Miguel De Sande, MD2,17; Coriolan Lebreton, MD14,18 ; Andres Redondo, MD ´ 2,19; Michel Fabbro, MD14,20; Maria-Pilar Barretina Ginesta, MD2,21 ; Philippe Follana, MD14,22; J. Alejandro Perez-Fidalgo, MD ´ 2,23 ; Manuel Rodrigues, MD14,24 ; Ana Santaballa, MD2,25; Renaud Sabatier, MD14,26 ; Maria Jose Bermejo-P ´ erez, MD ´ 2,27; Jean-Pierre Lotz, MD14,28; Beatriz Pardo, MD2,29; Gloria Marquina, MD2,30 ; Luisa Sanchez-Lorenzo, MD ´ 2,31 ; Marıa Quindos, MD ´ 2,32; Purificacion Est evez-Garc ıa, MD2,33 ; Eva Guerra Al´ıa, MD2,34; Luis Manso, MD2,35 ; Victoria Casado, MD2,36; Stefan Kommoss, MD6,37,38; Germana Tognon, MD9,39 ; Stephanie Henry, MD ´ 11,40 ; Ilan Bruchim, MD41,42; Ana Oaknin, MD2,43 ; and Fred´ eric Selle, MD ´ 14,44